SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                         Date of Report: April 30, 2007
                        (Date of earliest event reported)

                                VASOMEDICAL, INC.
             (Exact name of registrant as specified in its charter)


    Delaware                    0-18105                   11-2871434
(State or other              (Commission               (IRS Employer
 jurisdiction of              File Number)              Identification
 incorporation)                                            Number)


180 Linden Avenue, Westbury, New York                      11590
------------------------------------------         -----------------------
(Address of principal executive offices)                (Zip Code)



Registrant's telephone number including area code        (516) 997-4600
                                                      ----------------------

                                 Not applicable
                                 --------------
          (Former name or former address, if changed since last report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
    Exchange Act (17 CFR 240.14d-2(b)

[ ] Pre-commencement communications pursuant to Rule 13e-4c under the
    Exchange Act (17 CFR 240.13e-4c)




Item 5.02  Departure of Directors or Certain Officers; Election of
           Directors; Appointment of Certain Officers; Compensatory
           Arrangements of Certain Officers.

     (b) (i) On April 30, 2007, the Board of Directors  accepted the resignation
of Thomas Glover as its President and Chief Executive  Officer.  Mr. Glover will
continue to act as a director of the Company.

         (ii) On April 30, 2007, John C. K. Hui, PhD, Senior Vice President and
Chief  Technology  Officer  of the  Company  for in excess  of five  years and a
founder of the Company, was appointed by the Board of Directors as its President
and Chief Executive Officer, to serve at the pleasure of the Board.

                                   SIGNATURES

     Pursuant to the  requirements  of the  Securities  Exchange Act of 1934, as
amended,  the  Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

                                   VASOMEDICAL, INC.

                                   By: /s/ John C. K. Hui
                                       -------------------------------------
                                       John C. K. Hui
                                       President and Chief Executive Officer

Dated:   May 1, 2007